Advisors Asset Management Inc. Sells 3,706 Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Advisors Asset Management Inc. lessened its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACADGet Rating) by 13.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 24,491 shares of the biopharmaceutical company’s stock after selling 3,706 shares during the period. Advisors Asset Management Inc.’s holdings in ACADIA Pharmaceuticals were worth $345,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also bought and sold shares of ACAD. Strs Ohio raised its stake in ACADIA Pharmaceuticals by 21.7% in the second quarter. Strs Ohio now owns 67,200 shares of the biopharmaceutical company’s stock valued at $946,000 after buying an additional 12,000 shares during the period. Nisa Investment Advisors LLC bought a new stake in ACADIA Pharmaceuticals in the first quarter valued at approximately $152,000. Panagora Asset Management Inc. raised its stake in ACADIA Pharmaceuticals by 19.8% in the first quarter. Panagora Asset Management Inc. now owns 479,882 shares of the biopharmaceutical company’s stock valued at $11,623,000 after buying an additional 79,264 shares during the period. Diversified Trust Co raised its stake in ACADIA Pharmaceuticals by 26.2% in the second quarter. Diversified Trust Co now owns 26,309 shares of the biopharmaceutical company’s stock valued at $371,000 after buying an additional 5,464 shares during the period. Finally, Fox Run Management L.L.C. bought a new stake in ACADIA Pharmaceuticals in the first quarter valued at approximately $584,000. Institutional investors own 92.48% of the company’s stock.

Insider Activity

In other news, CEO Stephen Davis sold 2,804 shares of the stock in a transaction on Saturday, October 15th. The stock was sold at an average price of $15.81, for a total value of $44,331.24. Following the completion of the transaction, the chief executive officer now directly owns 79,009 shares in the company, valued at approximately $1,249,132.29. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 28.40% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts have issued reports on ACAD shares. Mizuho dropped their price objective on ACADIA Pharmaceuticals to $17.00 in a research note on Thursday, October 13th. Cowen decreased their target price on ACADIA Pharmaceuticals from $32.00 to $21.00 and set an “outperform” rating on the stock in a research report on Monday, August 8th. StockNews.com downgraded ACADIA Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. Loop Capital initiated coverage on ACADIA Pharmaceuticals in a research report on Tuesday, November 1st. They issued a “hold” rating and a $17.00 target price on the stock. Finally, Cowen decreased their target price on ACADIA Pharmaceuticals from $32.00 to $21.00 and set an “outperform” rating on the stock in a research report on Monday, August 8th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $21.90.

ACADIA Pharmaceuticals Price Performance

NASDAQ ACAD opened at $15.15 on Friday. The business has a fifty day moving average price of $16.31 and a two-hundred day moving average price of $16.25. ACADIA Pharmaceuticals Inc. has a fifty-two week low of $12.24 and a fifty-two week high of $28.06. The stock has a market capitalization of $2.45 billion, a PE ratio of -11.22 and a beta of 0.60.

ACADIA Pharmaceuticals (NASDAQ:ACADGet Rating) last released its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.01. ACADIA Pharmaceuticals had a negative return on equity of 47.09% and a negative net margin of 42.49%. The firm had revenue of $130.70 million during the quarter, compared to analysts’ expectations of $139.04 million. During the same period in the prior year, the company earned ($0.09) earnings per share. The company’s quarterly revenue was down .7% on a year-over-year basis. As a group, sell-side analysts expect that ACADIA Pharmaceuticals Inc. will post -1.31 earnings per share for the current year.

ACADIA Pharmaceuticals Profile

(Get Rating)

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

Read More

Want to see what other hedge funds are holding ACAD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ACADIA Pharmaceuticals Inc. (NASDAQ:ACADGet Rating).

Institutional Ownership by Quarter for ACADIA Pharmaceuticals (NASDAQ:ACAD)

Receive News & Ratings for ACADIA Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.